Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Mark Lovell to Alzheimer Disease

This is a "connection" page, showing publications Mark Lovell has written about Alzheimer Disease.

 
Connection Strength
  
 
 
9.763
  
  1. Ellison EM, Bradley-Whitman MA, Lovell MA. Single-Base Resolution Mapping of 5-Hydroxymethylcytosine Modifications in Hippocampus of Alzheimer's Disease Subjects. J Mol Neurosci. 2017 Oct; 63(2):185-197.
    View in: PubMed
    Score: 0.403
  2. Ellison EM, Abner EL, Lovell MA. Multiregional analysis of global 5-methylcytosine and 5-hydroxymethylcytosine throughout the progression of Alzheimer's disease. J Neurochem. 2017 02; 140(3):383-394.
    View in: PubMed
    Score: 0.387
  3. Lovell MA, Lynn BC, Fister S, Bradley-Whitman M, Murphy MP, Beckett TL, Norris CM. A Novel Small Molecule Modulator of Amyloid Pathology. J Alzheimers Dis. 2016 05 04; 53(1):273-87.
    View in: PubMed
    Score: 0.368
  4. Bradley-Whitman MA, Lovell MA. Biomarkers of lipid peroxidation in Alzheimer disease (AD): an update. Arch Toxicol. 2015 Jul; 89(7):1035-44.
    View in: PubMed
    Score: 0.342
  5. Bradley-Whitman MA, Abner E, Lynn BC, Lovell MA. A Novel Plasma Based Biomarker of Alzheimer's Disease. J Alzheimers Dis. 2015; 47(3):761-71.
    View in: PubMed
    Score: 0.335
  6. Bradley-Whitman MA, Timmons MD, Beckett TL, Murphy MP, Lynn BC, Lovell MA. Nucleic acid oxidation: an early feature of Alzheimer's disease. J Neurochem. 2014 Jan; 128(2):294-304.
    View in: PubMed
    Score: 0.308
  7. Bradley-Whitman MA, Lovell MA. Epigenetic changes in the progression of Alzheimer's disease. Mech Ageing Dev. 2013 Oct; 134(10):486-95.
    View in: PubMed
    Score: 0.306
  8. Lyubartseva G, Lovell MA. A potential role for zinc alterations in the pathogenesis of Alzheimer's disease. Biofactors. 2012 Mar-Apr; 38(2):98-106.
    View in: PubMed
    Score: 0.276
  9. Lovell MA, Soman S, Bradley MA. Oxidatively modified nucleic acids in preclinical Alzheimer's disease (PCAD) brain. Mech Ageing Dev. 2011 Aug; 132(8-9):443-8.
    View in: PubMed
    Score: 0.265
  10. Bradley MA, Xiong-Fister S, Markesbery WR, Lovell MA. Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression. Neurobiol Aging. 2012 Jun; 33(6):1034-44.
    View in: PubMed
    Score: 0.250
  11. Lovell MA. Memories of Dr. William R. Markesbery. Neuromolecular Med. 2011 Mar; 13(1):15-6.
    View in: PubMed
    Score: 0.244
  12. Bradley MA, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Radic Biol Med. 2010 Jun 15; 48(12):1570-6.
    View in: PubMed
    Score: 0.239
  13. Lovell MA. Similarities and differences between mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis. 2010; 19(1):219.
    View in: PubMed
    Score: 0.237
  14. Lynn BC, Wang J, Markesbery WR, Lovell MA. Quantitative changes in the mitochondrial proteome from subjects with mild cognitive impairment, early stage, and late stage Alzheimer's disease. J Alzheimers Dis. 2010; 19(1):325-39.
    View in: PubMed
    Score: 0.237
  15. Lyubartseva G, Smith JL, Markesbery WR, Lovell MA. Alterations of zinc transporter proteins ZnT-1, ZnT-4 and ZnT-6 in preclinical Alzheimer's disease brain. Brain Pathol. 2010 Mar; 20(2):343-50.
    View in: PubMed
    Score: 0.225
  16. Lovell MA. A potential role for alterations of zinc and zinc transport proteins in the progression of Alzheimer's disease. J Alzheimers Dis. 2009; 16(3):471-83.
    View in: PubMed
    Score: 0.221
  17. Dong J, Robertson JD, Markesbery WR, Lovell MA. Serum zinc in the progression of Alzheimer's disease. J Alzheimers Dis. 2008 Nov; 15(3):443-50.
    View in: PubMed
    Score: 0.219
  18. Shao C, Xiong S, Li GM, Gu L, Mao G, Markesbery WR, Lovell MA. Altered 8-oxoguanine glycosylase in mild cognitive impairment and late-stage Alzheimer's disease brain. Free Radic Biol Med. 2008 Sep 15; 45(6):813-9.
    View in: PubMed
    Score: 0.213
  19. Lovell MA, Lynn BC, Xiong S, Quinn JF, Kaye J, Markesbery WR. An aberrant protein complex in CSF as a biomarker of Alzheimer disease. Neurology. 2008 Jun 03; 70(23):2212-8.
    View in: PubMed
    Score: 0.211
  20. Lovell MA, Markesbery WR. Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J Neurosci Res. 2007 Nov 01; 85(14):3036-40.
    View in: PubMed
    Score: 0.204
  21. Lovell MA, Markesbery WR. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res. 2007; 35(22):7497-504.
    View in: PubMed
    Score: 0.203
  22. Markesbery WR, Lovell MA. Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch Neurol. 2007 Jul; 64(7):954-6.
    View in: PubMed
    Score: 0.199
  23. Markesbery WR, Lovell MA. DNA oxidation in Alzheimer's disease. Antioxid Redox Signal. 2006 Nov-Dec; 8(11-12):2039-45.
    View in: PubMed
    Score: 0.190
  24. Lovell MA, Smith JL, Markesbery WR. Elevated zinc transporter-6 in mild cognitive impairment, Alzheimer disease, and pick disease. J Neuropathol Exp Neurol. 2006 May; 65(5):489-98.
    View in: PubMed
    Score: 0.184
  25. Smith JL, Xiong S, Markesbery WR, Lovell MA. Altered expression of zinc transporters-4 and -6 in mild cognitive impairment, early and late Alzheimer's disease brain. Neuroscience. 2006 Jul 07; 140(3):879-88.
    View in: PubMed
    Score: 0.183
  26. Lovell MA, Markesbery WR. Ectopic expression of Musashi-1 in Alzheimer disease and Pick disease. J Neuropathol Exp Neurol. 2005 Aug; 64(8):675-80.
    View in: PubMed
    Score: 0.174
  27. Williams TI, Lynn BC, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol Aging. 2006 Aug; 27(8):1094-9.
    View in: PubMed
    Score: 0.173
  28. Lovell MA, Geiger H, Van Zant GE, Lynn BC, Markesbery WR. Isolation of neural precursor cells from Alzheimer's disease and aged control postmortem brain. Neurobiol Aging. 2006 Jul; 27(7):909-17.
    View in: PubMed
    Score: 0.173
  29. Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem. 2005 May; 93(4):953-62.
    View in: PubMed
    Score: 0.171
  30. Lovell MA, Smith JL, Xiong S, Markesbery WR. Alterations in zinc transporter protein-1 (ZnT-1) in the brain of subjects with mild cognitive impairment, early, and late-stage Alzheimer's disease. Neurotox Res. 2005; 7(4):265-71.
    View in: PubMed
    Score: 0.168
  31. Lovell MA, Xie C, Xiong S, Markesbery WR. Wilms' tumor suppressor (WT1) is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer's disease. Brain Res. 2003 Sep 05; 983(1-2):84-96.
    View in: PubMed
    Score: 0.153
  32. Lovell MA, Xie C, Xiong S, Markesbery WR. Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid. J Alzheimers Dis. 2003 Jun; 5(3):229-39.
    View in: PubMed
    Score: 0.150
  33. Lovell MA, Robertson JD, Buchholz BA, Xie C, Markesbery WR. Use of bomb pulse carbon-14 to age senile plaques and neurofibrillary tangles in Alzheimer's disease. Neurobiol Aging. 2002 Mar-Apr; 23(2):179-86.
    View in: PubMed
    Score: 0.138
  34. Lovell MA, Xie C, Markesbery WR. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging. 2001 Mar-Apr; 22(2):187-94.
    View in: PubMed
    Score: 0.128
  35. Lovell MA, Markesbery WR. Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer disease ventricular cerebrospinal fluid. Arch Neurol. 2001 Mar; 58(3):392-6.
    View in: PubMed
    Score: 0.128
  36. Lovell MA, Xie C, Markesbery WR. Decreased base excision repair and increased helicase activity in Alzheimer's disease brain. Brain Res. 2000 Feb 07; 855(1):116-23.
    View in: PubMed
    Score: 0.119
  37. Lovell MA, Xie C, Gabbita SP, Markesbery WR. Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain. Free Radic Biol Med. 2000 Feb 01; 28(3):418-27.
    View in: PubMed
    Score: 0.119
  38. Lovell MA, Gabbita SP, Markesbery WR. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J Neurochem. 1999 Feb; 72(2):771-6.
    View in: PubMed
    Score: 0.111
  39. Lovell MA, Xie C, Markesbery WR. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology. 1998 Dec; 51(6):1562-6.
    View in: PubMed
    Score: 0.110
  40. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci. 1998 Jun 11; 158(1):47-52.
    View in: PubMed
    Score: 0.106
  41. Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging. 1998 Jan-Feb; 19(1):33-6.
    View in: PubMed
    Score: 0.103
  42. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging. 1997 Sep-Oct; 18(5):457-61.
    View in: PubMed
    Score: 0.101
  43. Sompol P, Furman JL, Pleiss MM, Kraner SD, Artiushin IA, Batten SR, Quintero JE, Simmerman LA, Beckett TL, Lovell MA, Murphy MP, Gerhardt GA, Norris CM. Calcineurin/NFAT Signaling in Activated Astrocytes Drives Network Hyperexcitability in A?-Bearing Mice. J Neurosci. 2017 06 21; 37(25):6132-6148.
    View in: PubMed
    Score: 0.099
  44. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology. 1995 Aug; 45(8):1594-601.
    View in: PubMed
    Score: 0.087
  45. Lovell MA, Ehmann WD, Markesbery WR. Laser microprobe analysis of brain aluminum in Alzheimer's disease. Ann Neurol. 1993 Jan; 33(1):36-42.
    View in: PubMed
    Score: 0.073
  46. Lovell MA, Bradley MA, Fister SX. 4-Hydroxyhexenal (HHE) impairs glutamate transport in astrocyte cultures. J Alzheimers Dis. 2012; 32(1):139-46.
    View in: PubMed
    Score: 0.068
  47. Weidner AM, Bradley MA, Beckett TL, Niedowicz DM, Dowling AL, Matveev SV, LeVine H, Lovell MA, Murphy MP. RNA oxidation adducts 8-OHG and 8-OHA change with A?42 levels in late-stage Alzheimer's disease. PLoS One. 2011; 6(9):e24930.
    View in: PubMed
    Score: 0.067
  48. Smith CD, Chebrolu H, Andersen AH, Powell DA, Lovell MA, Xiong S, Gold BT. White matter diffusion alterations in normal women at risk of Alzheimer's disease. Neurobiol Aging. 2010 Jul; 31(7):1122-31.
    View in: PubMed
    Score: 0.054
  49. Sonnen JA, Breitner JC, Lovell MA, Markesbery WR, Quinn JF, Montine TJ. Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radic Biol Med. 2008 Aug 01; 45(3):219-30.
    View in: PubMed
    Score: 0.053
  50. Lovell MA, Markesbery WR. Oxidatively modified RNA in mild cognitive impairment. Neurobiol Dis. 2008 Feb; 29(2):169-75.
    View in: PubMed
    Score: 0.050
  51. Mao G, Pan X, Zhu BB, Zhang Y, Yuan F, Huang J, Lovell MA, Lee MP, Markesbery WR, Li GM, Gu L. Identification and characterization of OGG1 mutations in patients with Alzheimer's disease. Nucleic Acids Res. 2007; 35(8):2759-66.
    View in: PubMed
    Score: 0.049
  52. Liu X, Lovell MA, Lynn BC. Detection and quantification of endogenous cyclic DNA adducts derived from trans-4-hydroxy-2-nonenal in human brain tissue by isotope dilution capillary liquid chromatography nanoelectrospray tandem mass spectrometry. Chem Res Toxicol. 2006 May; 19(5):710-8.
    View in: PubMed
    Score: 0.046
  53. Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol. 2005 Nov; 58(5):730-5.
    View in: PubMed
    Score: 0.044
  54. Smith CD, Kryscio RJ, Schmitt FA, Lovell MA, Blonder LX, Rayens WS, Andersen AH. Longitudinal functional alterations in asymptomatic women at risk for Alzheimer's disease. J Neuroimaging. 2005 Jul; 15(3):271-7.
    View in: PubMed
    Score: 0.043
  55. Drake J, Petroze R, Castegna A, Ding Q, Keller JN, Markesbery WR, Lovell MA, Butterfield DA. 4-Hydroxynonenal oxidatively modifies histones: implications for Alzheimer's disease. Neurosci Lett. 2004 Feb 19; 356(3):155-8.
    View in: PubMed
    Score: 0.039
  56. Kelley ZD, Lovell MA, Lynn BC. Pharmacokinetic and metabolic analysis of an Alzheimer's disease therapeutic in rat serum via microfluidic CZE-MS. Biomed Chromatogr. 2022 Jan; 36(1):e5243.
    View in: PubMed
    Score: 0.033
  57. Lovell MA, Xie C, Markesbery WR. Acrolein, a product of lipid peroxidation, inhibits glucose and glutamate uptake in primary neuronal cultures. Free Radic Biol Med. 2000 Oct 15; 29(8):714-20.
    View in: PubMed
    Score: 0.031
  58. Rulon LL, Robertson JD, Lovell MA, Deibel MA, Ehmann WD, Markesber WR. Serum zinc levels and Alzheimer's disease. Biol Trace Elem Res. 2000; 75(1-3):79-85.
    View in: PubMed
    Score: 0.030
  59. Gabbita SP, Aksenov MY, Lovell MA, Markesbery WR. Decrease in peptide methionine sulfoxide reductase in Alzheimer's disease brain. J Neurochem. 1999 Oct; 73(4):1660-6.
    View in: PubMed
    Score: 0.029
  60. Gabbita SP, Lovell MA, Markesbery WR. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem. 1998 Nov; 71(5):2034-40.
    View in: PubMed
    Score: 0.027
  61. Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res. 1998 Jan; 23(1):81-8.
    View in: PubMed
    Score: 0.026
  62. Kryscio RJ, Abner EL, Caban-Holt A, Lovell M, Goodman P, Darke AK, Yee M, Crowley J, Schmitt FA. Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE). JAMA Neurol. 2017 05 01; 74(5):567-573.
    View in: PubMed
    Score: 0.025
  63. Williams TI, Lovell MA, Lynn BC. Analysis of derivatized biogenic aldehydes by LC tandem mass spectrometry. Anal Chem. 2005 May 15; 77(10):3383-9.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)